Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroğlu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. Huddart RA, et al. Among authors: chien d. Future Oncol. 2021 Jan;17(2):137-149. doi: 10.2217/fon-2020-0795. Epub 2020 Sep 17. Future Oncol. 2021. PMID: 32938232 Clinical Trial.
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A. Eggermont AM, et al. Among authors: chien d. Future Oncol. 2022 Mar;18(8):903-913. doi: 10.2217/fon-2021-1286. Epub 2022 Jan 25. Future Oncol. 2022. PMID: 35073733
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Tannir NM, et al. Among authors: chien d. J Immunother Cancer. 2022 Apr;10(4):e004419. doi: 10.1136/jitc-2021-004419. J Immunother Cancer. 2022. PMID: 35444058 Free PMC article. Clinical Trial.
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Siefker-Radtke AO, et al. Among authors: chien d. Eur Urol. 2022 Oct;82(4):365-373. doi: 10.1016/j.eururo.2022.05.002. Epub 2022 May 25. Eur Urol. 2022. PMID: 35643589 Clinical Trial.
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Burmester G, Drescher E, Hrycaj P, Chien D, Pan Z, Cohen S. Burmester G, et al. Among authors: chien d. Clin Rheumatol. 2020 Nov;39(11):3341-3352. doi: 10.1007/s10067-020-05305-y. Epub 2020 Sep 2. Clin Rheumatol. 2020. PMID: 32876780 Free PMC article. Clinical Trial.
236 results